Abeid Athman (Omar).· @bin_abeid · X·· 14 小时前评分70
正文 · 原文
In DeLLphi-305: The combination of Tarlatamab+ Durvalumab improves both OS (21 vs 12 months HR 0.42) and PFS in ES-SCLC. This is remarkable in such a lethal disease with high recurrence rates and mortality. #ESMO2026 #ESMOAmbassadors @myESMO @StephenVLiu @tompowles1 @FAndreMD
29 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Abeid Athman (Omar). · x.com